Condition: Alzheimer Disease · Sponsor: Eli Lilly and Company
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Peking University Third Hospital | Beijing, China | Recruiting |
| The First Hospital of Jilin University | Changchun, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, China | Not Yet Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, China | Recruiting |
| 2nd Affiliated Hospital Chongqing Medical University | Chongqing, China | Not Yet Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, China | Not Yet Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, China | Not Yet Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, China | Not Yet Recruiting |
| Anhui Provincial Hospital | Hefei, China | Recruiting |
| The Second Hospital of Jiaxing | Jiaxing, China | Recruiting |
| Jinan Central Hospital | Jinan, China | Recruiting |
| The Second Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07571161